New PET-MRI tracer could sharpen view of Kids' brain tumors

NCT ID NCT05555550

Recruiting now Diagnosis Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial at Children's Hospital of Philadelphia is testing whether a radioactive tracer called 18F-Fluciclovine (Axumin) can improve PET-MRI scans for children and young adults with low-grade glioma. About 30 participants will receive the tracer before starting treatment, then again at 3 months and 1 year. The goal is to see if changes in tracer uptake better reflect tumor response than standard MRI alone, while also checking safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Fluciclovine (Axumin), a radioactive tracer injected before PET-MRI imaging
What this could lead to: If successful, this imaging method could help doctors see sooner whether a child's brain tumor is responding to treatment, potentially guiding therapy adjustments.
What could go wrong: This is a very early, small study (30 participants) focused on imaging accuracy, not treatment. The tracer may not prove more useful than standard MRI, and safety in children is still being checked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma low grade glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA GLIOMA INTRACRANIAL GLIOMA, MALIGNANT LOW GRADE GLIOMA LOW GRADE GLIOMA OF BRAIN

Contacts and locations

Locations

The Children s Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.